
Deep dive into business development in biotech with James Lee
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Business development is an essential process for biotech companies to build relationships with partners and create value from the deal structures that are based on science. We are taking a deep dive with James Lee into the mechanics and the framework that James uses for business development.
James founded Bridge Biotherapeutics Inc. in 2015 and he currently serves as the CEO. Bridge has been recognized with the continuous advancement of clinical-stage programs focused on pulmonary fibrosis, lung cancer, and immunology. In 2019, James successfully orchestrated the licensing-out deal with Boehringer Ingelheim, which marked as one of the largest global deals on a single compound in Korea.
Pas encore de commentaire